-
公开(公告)号：US20240066113A1
公开(公告)日：2024-02-29
申请号：US18029758
申请日：2022-04-12
Applicant: ACADEMIA SINICA
Inventor： Chi-Huey WONG , Chung-Yi WU , Che MA , Chen-Yu FAN
IPC: A61K39/215 , A61K9/127 , A61P31/14 , C07K14/165
CPC classification number: A61K39/215 , A61K9/127 , A61P31/14 , C07K14/165 , A61K2039/545
Abstract: The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof.
-
公开(公告)号：US20150335728A1
公开(公告)日：2015-11-26
申请号：US14182296
申请日：2014-02-18
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Che MA , Cheng-Chi WANG , Juine-Ruey CHEN
IPC: A61K39/145 , C12N7/00
CPC classification number: A61K39/145 , A61K39/12 , A61K2039/55505 , C07K16/1018 , C07K2317/76 , C12N7/00 , C12N2740/11034 , C12N2740/16034 , C12N2760/16122 , C12N2760/16134 , C12N2760/16171 , C12N2770/24134 , Y02A50/386
Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.
Abstract translation: 提供了包含部分糖基化的病毒糖蛋白的免疫原性组合物，其用作抗病毒疫苗。 使用单糖，二糖或三糖基化的病毒表面糖蛋白和多肽配制的疫苗甚至可以跨毒株提供有效和广泛的防病毒保护。 公开了包含单糖基化血凝素多肽和由其产生的疫苗的药物组合物及其用于预防或治疗病毒感染的方法。 公开了用于流感病毒HA，NA和M2，RSV蛋白F，G和SH，登革病毒糖蛋白M或E，丙型肝炎病毒糖蛋白E1或E2和HIV糖蛋白gp120和gp41的方法和组合物。
-
公开(公告)号：US20250082744A1
公开(公告)日：2025-03-13
申请号：US18927447
申请日：2024-10-25
Applicant: ACADEMIA SINICA
Inventor： Chi-Huey WONG , Hsin-Yu LIAO , Shih-Chi WANG , Yi-An KO , Kuo-I LIN , Che MA , Ting-Jen CHENG
IPC: A61K39/145 , A61K39/00 , A61P31/16 , C07K14/005
Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
-
4.发明申请COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY 审中-公开与通用胶囊相关的组合物和方法，以提高抗体效能公开(公告)号：US20160280794A1
公开(公告)日：2016-09-29
申请号：US15011544
申请日：2016-01-30
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU , Che MA , Han-Chung WU
CPC classification number: C07K16/30 , A61K45/06 , C07K16/1018 , C07K16/18 , C07K16/241 , C07K16/2887 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C12N9/24 , C12P21/005 , C12Y302/01 , C12Y302/01051
Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
Abstract translation: 本公开涉及包含抗体或其结合片段的组合物和使用方法，其还包含通用Fc糖形式。
-
公开(公告)号：US20240316179A1
公开(公告)日：2024-09-26
申请号：US18662436
申请日：2024-05-13
Applicant: ACADEMIA SINICA
Inventor： Chi-Huey WONG , Hsin-Yu LIAO , Shih-Chi WANG , Yi-An KO , Kuo-I LIN , Che MA , Ting-Jen CHENG
IPC: A61K39/145 , A61K39/00 , A61P31/16 , C07K14/005
CPC classification number: A61K39/145 , A61P31/16 , C07K14/005 , A61K2039/575
Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
-
Patent Agency Ranking
公开(公告)号：US20240100147A1
公开(公告)日：2024-03-28
申请号：US18501578
申请日：2023-11-03
Applicant: ACADEMIA SINICA
Inventor： Chi-Huey WONG , Hsin-Yu LIAO , Shih-Chi WANG , Yi-An KO , Kuo-I LIN , Che MA , Ting-Jen CHENG
IPC: A61K39/145 , A61P31/16 , C07K14/005
CPC classification number: A61K39/145 , A61P31/16 , C07K14/005 , A61K2039/575
Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
-
7.发明申请公开(公告)号：US20180265590A1
公开(公告)日：2018-09-20
申请号：US15982141
申请日：2018-05-17
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU , Che MA , Han-Chung WU
CPC classification number: C07K16/30 , A61K45/06 , C07K16/1018 , C07K16/18 , C07K16/241 , C07K16/2887 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C12N9/24 , C12P21/005 , C12Y302/01 , C12Y302/01051
Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
-
公开(公告)号：US20240228591A1
公开(公告)日：2024-07-11
申请号：US18403419
申请日：2024-01-03
Applicant: ACADEMIA SINICA
Inventor： Kuo-I LIN , Che MA , Chi-Huey WONG , Szu-Wen WANG , Yi-Hsuan CHANG , Xiaorui CHEN , Han-Yi HUANG
CPC classification number: C07K16/10 , A61K39/42 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-COV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
-
公开(公告)号：US20230346872A1
公开(公告)日：2023-11-02
申请号：US17922977
申请日：2021-05-06
Applicant: Academia Sinica
Inventor： Che MA , Jia-Tsrong JAN
IPC: A61K36/896 , A61K45/06 , A61P31/14
CPC classification number: A61K36/896 , A61K45/06 , A61P31/14
Abstract: Disclosed herein is a method for treating or preventing a coronavirus infection, which comprises administering to a subject in need thereof an effective amount of a composition comprising Flt3 receptor interacting lectin (FRIL) from Lablab purpureus. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, a Lablab purpureus FRIL, and an additional therapeutic agent.
-
10.发明申请公开(公告)号：US20200165649A1
公开(公告)日：2020-05-28
申请号：US16591229
申请日：2019-10-02
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU , Che MA
IPC: C12P19/14 , C12N9/24 , C07K16/32 , C07K16/30 , C07K16/28 , C07K16/24 , C07K16/10 , C07K16/00 , A61K45/06 , A61K39/42 , A61K39/395 , C07K16/18
Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.018 seconds)
